-
1
-
-
0041409703
-
Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials
-
12927565 10.1016/S0305-7372(03)00074-4 1:CAS:528:DC%2BD3sXmsVCns7s%3D
-
Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S (2003) Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29(4):241-252
-
(2003)
Cancer Treat Rev
, vol.29
, Issue.4
, pp. 241-252
-
-
Wheatley, K.1
Ives, N.2
Hancock, B.3
Gore, M.4
Eggermont, A.5
Suciu, S.6
-
2
-
-
1842533233
-
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma
-
15014018 10.1158/1078-0432.CCR-1103-3 1:CAS:528:DC%2BD2cXhvFCltr4%3D
-
Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U (2004) A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10(5):1670-1677
-
(2004)
Clin Cancer Res
, vol.10
, Issue.5
, pp. 1670-1677
-
-
Kirkwood, J.M.1
Manola, J.2
Ibrahim, J.3
Sondak, V.4
Ernstoff, M.S.5
Rao, U.6
-
3
-
-
46749103710
-
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial
-
18620949 10.1016/S0140-6736(08)61033-8 1:CAS:528:DC%2BD1cXosVynurk%3D
-
Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Sales F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372(9633):117-126
-
(2008)
Lancet
, vol.372
, Issue.9633
, pp. 117-126
-
-
Eggermont, A.M.1
Suciu, S.2
Santinami, M.3
Testori, A.4
Kruit, W.H.5
Marsden, J.6
Punt, C.J.7
Sales, F.8
Gore, M.9
Mackie, R.10
Kusic, Z.11
Dummer, R.12
Hauschild, A.13
Musat, E.14
Spatz, A.15
Keilholz, U.16
-
4
-
-
42449105247
-
Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease
-
18320602 10.1002/cncr.23399 1:CAS:528:DC%2BD1cXmtFOlu74%3D
-
Anaya DA, Xing Y, Feng L, Huang X, Camacho LH, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Cormier JN (2008) Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer 112(9):2030-2037
-
(2008)
Cancer
, vol.112
, Issue.9
, pp. 2030-2037
-
-
Anaya, D.A.1
Xing, Y.2
Feng, L.3
Huang, X.4
Camacho, L.H.5
Ross, M.I.6
Gershenwald, J.E.7
Lee, J.E.8
Mansfield, P.F.9
Cormier, J.N.10
-
5
-
-
25844465690
-
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): Randomised controlled trial
-
16198768 10.1016/S0140-6736(05)67482-X 1:CAS:528:DC%2BD2MXhtVGrsrbL
-
Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D (2005) Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366(9492):1189-1196
-
(2005)
Lancet
, vol.366
, Issue.9492
, pp. 1189-1196
-
-
Eggermont, A.M.1
Suciu, S.2
Mackie, R.3
Ruka, W.4
Testori, A.5
Kruit, W.6
Punt, C.J.7
Delauney, M.8
Sales, F.9
Groenewegen, G.10
Ruiter, D.J.11
Jagiello, I.12
Stoitchkov, K.13
Keilholz, U.14
Lienard, D.15
-
6
-
-
84655168007
-
Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991
-
22056637 10.1016/j.ejca.2011.09.028 1:CAS:528:DC%2BC38XhtVCiuw%3D%3D
-
Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Sales F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A (2012) Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48(2):218-225
-
(2012)
Eur J Cancer
, vol.48
, Issue.2
, pp. 218-225
-
-
Eggermont, A.M.1
Suciu, S.2
Testori, A.3
Kruit, W.H.4
Marsden, J.5
Punt, C.J.6
Santinami, M.7
Sales, F.8
Schadendorf, D.9
Patel, P.10
Dummer, R.11
Robert, C.12
Keilholz, U.13
Yver, A.14
Spatz, A.15
-
7
-
-
77956196304
-
Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
-
discussion 465-466
-
McMasters KM, Edwards MJ, Ross MI, Reintgen DS, Martin RC, 2nd, Urist MM, Noyes RD, Sussman JJ, Stromberg AJ, Scoggins CR (2010) Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. Ann Surg 252(3):460-465; discussion 465-466
-
(2010)
Ann Surg
, vol.252
, Issue.3
, pp. 460-465
-
-
McMasters, K.M.1
Edwards, M.J.2
Ross, M.I.3
Reintgen, D.S.4
Martin II, R.C.5
Urist, M.M.6
Noyes, R.D.7
Sussman, J.J.8
Stromberg, A.J.9
Scoggins, C.R.10
-
8
-
-
35649015750
-
Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials
-
abstract 8526
-
Wheatley KIN, Eggermont A (2007) Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. ASCO Annual Meeting Proceedings Part 1. J Clin Oncol 25(suppl 18S):abstract 8526
-
(2007)
ASCO Annual Meeting Proceedings Part 1. J Clin Oncol
, vol.25
, Issue.SUPPL. 18S
-
-
Wheatley, K.I.N.1
Eggermont, A.2
-
9
-
-
34347272251
-
Interferon-alpha and cancer: Mechanisms of action and new perspectives of clinical use
-
17532550 10.1016/j.biochi.2007.04.006 1:CAS:528:DC%2BD2sXnsFKrurY%3D
-
Ferrantini M, Capone I, Belardelli F (2007) Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89(6-7):884-893
-
(2007)
Biochimie
, vol.89
, Issue.6-7
, pp. 884-893
-
-
Ferrantini, M.1
Capone, I.2
Belardelli, F.3
-
10
-
-
85047689957
-
The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse
-
12865406 1:CAS:528:DC%2BD3sXlslWlt7s%3D
-
Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, Badgwell B, Parihar R, Hu Y, Becknell B, Abood G, Chaudhury AR, Magro C, Durbin J, Carson WE 3rd (2003) The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Investig 112(2):170-180
-
(2003)
J Clin Investig
, vol.112
, Issue.2
, pp. 170-180
-
-
Lesinski, G.B.1
Anghelina, M.2
Zimmerer, J.3
Bakalakos, T.4
Badgwell, B.5
Parihar, R.6
Hu, Y.7
Becknell, B.8
Abood, G.9
Chaudhury, A.R.10
Magro, C.11
Durbin, J.12
Carson III, W.E.13
-
11
-
-
0345829305
-
The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line
-
14732359 10.1016/j.jss.2003.09.005 1:CAS:528:DC%2BD2cXltVGhsw%3D%3D
-
Badgwell B, Lesinski GB, Magro C, Abood G, Skaf A, Carson W 3rd (2004) The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line. J Surg Res 116(1):129-136
-
(2004)
J Surg Res
, vol.116
, Issue.1
, pp. 129-136
-
-
Badgwell, B.1
Lesinski, G.B.2
Magro, C.3
Abood, G.4
Skaf, A.5
Carson III, W.6
-
12
-
-
10744221302
-
Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: Implications for cancer vaccines
-
14555505 1:CAS:528:DC%2BD3sXotVShsLk%3D
-
Astsaturov I, Petrella T, Bagriacik EU, de Benedette M, Uger R, Lumber G, Berinstein N, Elias I, Iscoe N, Hammond C, Hamilton P, Spaner DE (2003) Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines. Clin Cancer Res 9(12):4347-4355
-
(2003)
Clin Cancer Res
, vol.9
, Issue.12
, pp. 4347-4355
-
-
Astsaturov, I.1
Petrella, T.2
Bagriacik, E.U.3
De Benedette, M.4
Uger, R.5
Lumber, G.6
Berinstein, N.7
Elias, I.8
Iscoe, N.9
Hammond, C.10
Hamilton, P.11
Spaner, D.E.12
-
13
-
-
58149138892
-
Adjuvant therapy of melanoma with interferon: Lessons of the past decade
-
18954464 10.1186/1479-5876-6-62
-
Ascierto PA, Kirkwood JM (2008) Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 6:62
-
(2008)
J Transl Med
, vol.6
, pp. 62
-
-
Ascierto, P.A.1
Kirkwood, J.M.2
-
14
-
-
32644454916
-
Prognostic significance of autoimmunity during treatment of melanoma with interferon
-
16481638 10.1056/NEJMoa053007 1:CAS:528:DC%2BD28XhsVWrsrw%3D
-
Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354(7):709-718
-
(2006)
N Engl J Med
, vol.354
, Issue.7
, pp. 709-718
-
-
Gogas, H.1
Ioannovich, J.2
Dafni, U.3
Stavropoulou-Giokas, C.4
Frangia, K.5
Tsoutsos, D.6
Panagiotou, P.7
Polyzos, A.8
Papadopoulos, O.9
Stratigos, A.10
Markopoulos, C.11
Bafaloukos, D.12
Pectasides, D.13
Fountzilas, G.14
Kirkwood, J.M.15
-
15
-
-
33745989541
-
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses
-
16809739 10.1200/JCO.2005.05.2498 1:CAS:528:DC%2BD28XnslKhsL0%3D
-
Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, Kirkwood JM (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24(19):3164-3171
-
(2006)
J Clin Oncol
, vol.24
, Issue.19
, pp. 3164-3171
-
-
Moschos, S.J.1
Edington, H.D.2
Land, S.R.3
Rao, U.N.4
Jukic, D.5
Shipe-Spotloe, J.6
Kirkwood, J.M.7
-
16
-
-
34249709048
-
Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma
-
17488182 10.1371/journal.pmed.0040176
-
Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP (2007) Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 4(5):e176
-
(2007)
PLoS Med
, vol.4
, Issue.5
, pp. 176
-
-
Critchley-Thorne, R.J.1
Yan, N.2
Nacu, S.3
Weber, J.4
Holmes, S.P.5
Lee, P.P.6
-
17
-
-
4444226259
-
Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy
-
15339971 10.1093/jnci/djh252 1:CAS:528:DC%2BD2cXnsVyht7k%3D
-
Lesinski GB, Kondadasula SV, Crespin T, Shen L, Kendra K, Walker M, Carson WE 3rd (2004) Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Cancer Inst 96(17):1331-1342
-
(2004)
J Natl Cancer Inst
, vol.96
, Issue.17
, pp. 1331-1342
-
-
Lesinski, G.B.1
Kondadasula, S.V.2
Crespin, T.3
Shen, L.4
Kendra, K.5
Walker, M.6
Carson III, W.E.7
-
18
-
-
52949111844
-
Inteferons pen the JAK-STAT pathway
-
18765289 10.1016/j.semcdb.2008.08.010 1:CAS:528:DC%2BD1cXhtFOrur%2FJ
-
Schindler C, Plumlee C (2008) Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol 19(4):311-318
-
(2008)
Semin Cell Dev Biol
, vol.19
, Issue.4
, pp. 311-318
-
-
Schindler, C.1
Plumlee, C.2
-
19
-
-
17644402442
-
Type i interferons (alpha/beta) in immunity and autoimmunity
-
15771573 10.1146/annurev.immunol.23.021704.115843 1:CAS:528: DC%2BD2MXktFOjur8%3D
-
Theofilopoulos AN, Baccala R, Beutler B, Kono DH (2005) Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23:307-336
-
(2005)
Annu Rev Immunol
, vol.23
, pp. 307-336
-
-
Theofilopoulos, A.N.1
Baccala, R.2
Beutler, B.3
Kono, D.H.4
-
20
-
-
41649103890
-
Regulation of innate immunity by suppressor of cytokine signaling (SOCS) proteins
-
18406369 10.1016/j.imbio.2007.10.008 1:CAS:528:DC%2BD1cXnsVGmsb8%3D
-
Dalpke A, Heeg K, Bartz H, Baetz A (2008) Regulation of innate immunity by suppressor of cytokine signaling (SOCS) proteins. Immunobiology 213(3-4):225-235
-
(2008)
Immunobiology
, vol.213
, Issue.3-4
, pp. 225-235
-
-
Dalpke, A.1
Heeg, K.2
Bartz, H.3
Baetz, A.4
-
21
-
-
34247107684
-
IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins
-
17404264 1:CAS:528:DC%2BD2sXjslWjs7k%3D
-
Zimmerer JM, Lesinski GB, Kondadasula SV, Karpa VI, Lehman A, Raychaudhury A, Becknell B, Carson WE 3rd (2007) IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins. J Immunol 178(8):4832-4845
-
(2007)
J Immunol
, vol.178
, Issue.8
, pp. 4832-4845
-
-
Zimmerer, J.M.1
Lesinski, G.B.2
Kondadasula, S.V.3
Karpa, V.I.4
Lehman, A.5
Raychaudhury, A.6
Becknell, B.7
Carson III, W.E.8
-
22
-
-
0033104946
-
Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1
-
10029571 1:CAS:528:DyaK1MXhsFertbs%3D
-
Ito S, Ansari P, Sakatsume M, Dickensheets H, Vazquez N, Donnelly RP, Larner AC, Finbloom DS (1999) Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93(5):1456-1463
-
(1999)
Blood
, vol.93
, Issue.5
, pp. 1456-1463
-
-
Ito, S.1
Ansari, P.2
Sakatsume, M.3
Dickensheets, H.4
Vazquez, N.5
Donnelly, R.P.6
Larner, A.C.7
Finbloom, D.S.8
-
23
-
-
13044290651
-
Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: Evidence for an IL-10-induced pathway that is independent of STAT protein activation
-
10515892 1:CAS:528:DyaK1MXmslantbc%3D
-
Cassatella MA, Gasperini S, Bovolenta C, Calzetti F, Vollebregt M, Scapini P, Marchi M, Suzuki R, Suzuki A, Yoshimura A (1999) Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood 94(8):2880-2889
-
(1999)
Blood
, vol.94
, Issue.8
, pp. 2880-2889
-
-
Cassatella, M.A.1
Gasperini, S.2
Bovolenta, C.3
Calzetti, F.4
Vollebregt, M.5
Scapini, P.6
Marchi, M.7
Suzuki, R.8
Suzuki, A.9
Yoshimura, A.10
-
24
-
-
27144502396
-
TGF-beta1 inhibits T-bet induction by IFN-gamma in murine CD4 + T cells through the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-1
-
16237056 1:CAS:528:DC%2BD2MXhtFahurrJ
-
Park IK, Shultz LD, Letterio JJ, Gorham JD (2005) TGF-beta1 inhibits T-bet induction by IFN-gamma in murine CD4 + T cells through the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-1. J Immunol 175(9):5666-5674
-
(2005)
J Immunol
, vol.175
, Issue.9
, pp. 5666-5674
-
-
Park, I.K.1
Shultz, L.D.2
Letterio, J.J.3
Gorham, J.D.4
-
25
-
-
0347296131
-
The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro
-
12646633 1:CAS:528:DC%2BD3sXitFKltLw%3D
-
Fox SW, Haque SJ, Lovibond AC, Chambers TJ (2003) The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. J Immunol 170(7):3679-3687
-
(2003)
J Immunol
, vol.170
, Issue.7
, pp. 3679-3687
-
-
Fox, S.W.1
Haque, S.J.2
Lovibond, A.C.3
Chambers, T.J.4
-
26
-
-
4344710617
-
Regulation of gene expression by pegylated IFN-alpha2b and IFN-alpha2b in human peripheral blood mononuclear cells
-
15320959 10.1089/1079990041689638 1:CAS:528:DC%2BD2cXms12jt70%3D
-
Brassard DL, Delorenzo MM, Cox S, Leaman DW, Sun Y, Ding W, Gavor S, Spond J, Goodsaid F, Bordens R, Grace MJ (2004) Regulation of gene expression by pegylated IFN-alpha2b and IFN-alpha2b in human peripheral blood mononuclear cells. J Interferon Cytokine Res 24(8):455-469
-
(2004)
J Interferon Cytokine Res
, vol.24
, Issue.8
, pp. 455-469
-
-
Brassard, D.L.1
Delorenzo, M.M.2
Cox, S.3
Leaman, D.W.4
Sun, Y.5
Ding, W.6
Gavor, S.7
Spond, J.8
Goodsaid, F.9
Bordens, R.10
Grace, M.J.11
-
27
-
-
33947380550
-
Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy
-
17267482 10.1128/JVI.02640-06 1:CAS:528:DC%2BD2sXjslWqs74%3D
-
Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, Stephens MJ, McClintick JN, Edenberg HJ, Li L, Tavis JE, Howell C, Belle SH (2007) Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 81(7):3391-3401
-
(2007)
J Virol
, vol.81
, Issue.7
, pp. 3391-3401
-
-
Taylor, M.W.1
Tsukahara, T.2
Brodsky, L.3
Schaley, J.4
Sanda, C.5
Stephens, M.J.6
McClintick, J.N.7
Edenberg, H.J.8
Li, L.9
Tavis, J.E.10
Howell, C.11
Belle, S.H.12
-
28
-
-
40949098538
-
2
-
18316567 10.1158/1078-0432.CCR-07-4178 1:CAS:528:DC%2BD1cXislSrsLs%3D
-
2. Clin Cancer Res 14(5):1438-1445
-
(2008)
Clin Cancer Res
, vol.14
, Issue.5
, pp. 1438-1445
-
-
Zimmerer, J.M.1
Lehman, A.M.2
Ruppert, A.S.3
Noble, C.W.4
Olencki, T.5
Walker, M.J.6
Kendra, K.7
Carson III, W.E.8
-
29
-
-
12144288875
-
Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction
-
15014010 10.1158/1078-0432.CCR-0610-3 1:CAS:528:DC%2BD2cXhvFClsbw%3D
-
Keilholz U, Goldin-Lang P, Bechrakis NE, Max N, Letsch A, Schmittel A, Scheibenbogen C, Heufelder K, Eggermont A, Thiel E (2004) Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res 10(5):1605-1612
-
(2004)
Clin Cancer Res
, vol.10
, Issue.5
, pp. 1605-1612
-
-
Keilholz, U.1
Goldin-Lang, P.2
Bechrakis, N.E.3
Max, N.4
Letsch, A.5
Schmittel, A.6
Scheibenbogen, C.7
Heufelder, K.8
Eggermont, A.9
Thiel, E.10
-
30
-
-
67449138506
-
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon
-
19509353 10.1093/jnci/djp132 1:CAS:528:DC%2BD1MXnslKjtbY%3D
-
Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Sales F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM (2009) Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 101(12):869-877
-
(2009)
J Natl Cancer Inst
, vol.101
, Issue.12
, pp. 869-877
-
-
Bouwhuis, M.G.1
Suciu, S.2
Collette, S.3
Aamdal, S.4
Kruit, W.H.5
Bastholt, L.6
Stierner, U.7
Sales, F.8
Patel, P.9
Punt, C.J.10
Hernberg, M.11
Spatz, A.12
Ten Hagen, T.L.13
Hansson, J.14
Eggermont, A.M.15
-
31
-
-
77952469658
-
Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: Prognostic significance of autoantibodies-EORTC 18991
-
20385998 10.1200/JCO.2009.24.6264 1:CAS:528:DC%2BC3cXnsFOnt74%3D
-
Bouwhuis MG, Suciu S, Testori A, Kruit WH, Sales F, Patel P, Punt CJ, Santinami M, Spatz A, Ten Hagen TL, Eggermont AM (2010) Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies-EORTC 18991. J Clin Oncol 28(14):2460-2466
-
(2010)
J Clin Oncol
, vol.28
, Issue.14
, pp. 2460-2466
-
-
Bouwhuis, M.G.1
Suciu, S.2
Testori, A.3
Kruit, W.H.4
Sales, F.5
Patel, P.6
Punt, C.J.7
Santinami, M.8
Spatz, A.9
Ten Hagen, T.L.10
Eggermont, A.M.11
-
32
-
-
79251599240
-
Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: A corollary study to EORTC trial 18952
-
21087856 10.1016/j.ejca.2010.10.005 1:CAS:528:DC%2BC3MXhtlSru7c%3D
-
Bouwhuis MG, Suciu S, Kruit W, Sales F, Stoitchkov K, Patel P, Cocquyt V, Thomas J, Lienard D, Eggermont AM, Ghanem G (2011) Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952. Eur J Cancer 47(3):361-368
-
(2011)
Eur J Cancer
, vol.47
, Issue.3
, pp. 361-368
-
-
Bouwhuis, M.G.1
Suciu, S.2
Kruit, W.3
Sales, F.4
Stoitchkov, K.5
Patel, P.6
Cocquyt, V.7
Thomas, J.8
Lienard, D.9
Eggermont, A.M.10
Ghanem, G.11
-
33
-
-
79960701540
-
Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-alpha (EORTC 18952) and prognostic value on treatment outcome
-
21546857 10.1097/CMR.0b013e328346c17f 1:CAS:528:DC%2BC3MXos1amtro%3D
-
Bouwhuis MG, Collette S, Suciu S, de Groot ER, Kruit WH, Ten Hagen TL, Aarden LA, Eggermont AM, Swaak AJ (2011) Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-alpha (EORTC 18952) and prognostic value on treatment outcome. Melanoma Res 21(4):344-351
-
(2011)
Melanoma Res
, vol.21
, Issue.4
, pp. 344-351
-
-
Bouwhuis, M.G.1
Collette, S.2
Suciu, S.3
De Groot, E.R.4
Kruit, W.H.5
Ten Hagen, T.L.6
Aarden, L.A.7
Eggermont, A.M.8
Swaak, A.J.9
-
34
-
-
80054705401
-
Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4(+) and CD8(+) T cells
-
21604070 10.1007/s00262-011-1034-2 1:CAS:528:DC%2BC3MXhtVOrtLbN
-
Guenterberg KD, Lesinski GB, Mundy-Bosse BL, Karpa VI, Jaime-Ramirez AC, Wei L, Carson WE 3rd (2011) Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4(+) and CD8(+) T cells. Cancer Immunol Immunother 60(9):1281-1288
-
(2011)
Cancer Immunol Immunother
, vol.60
, Issue.9
, pp. 1281-1288
-
-
Guenterberg, K.D.1
Lesinski, G.B.2
Mundy-Bosse, B.L.3
Karpa, V.I.4
Jaime-Ramirez, A.C.5
Wei, L.6
Carson III, W.E.7
-
35
-
-
77955526258
-
Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment
-
20712892 10.1186/1479-5876-8-76
-
Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, Capone M, Caraco C, Calemma R, Beneduce G, Cerrone M, De Rosa V, Palmieri G, Castello G, Kirkwood JM, Marincola FM, Mozzillo N (2010) Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med 8:76
-
(2010)
J Transl Med
, vol.8
, pp. 76
-
-
Ascierto, P.A.1
Napolitano, M.2
Celentano, E.3
Simeone, E.4
Gentilcore, G.5
Daponte, A.6
Capone, M.7
Caraco, C.8
Calemma, R.9
Beneduce, G.10
Cerrone, M.11
De Rosa, V.12
Palmieri, G.13
Castello, G.14
Kirkwood, J.M.15
Marincola, F.M.16
Mozzillo, N.17
-
36
-
-
33644988431
-
Characterization of CD4 + CD25 + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma
-
16505437 10.1200/JCO.2005.03.6830 1:CAS:528:DC%2BD28XislGgsbc%3D
-
Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL (2006) Characterization of CD4 + CD25 + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24(7):1169-1177
-
(2006)
J Clin Oncol
, vol.24
, Issue.7
, pp. 1169-1177
-
-
Cesana, G.C.1
Deraffele, G.2
Cohen, S.3
Moroziewicz, D.4
Mitcham, J.5
Stoutenburg, J.6
Cheung, K.7
Hesdorffer, C.8
Kim-Schulze, S.9
Kaufman, H.L.10
-
37
-
-
34447125038
-
Long-term protective effect of mature DC-LAMP + dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma
-
17606713 10.1158/1078-0432.CCR-07-0358 1:CAS:528:DC%2BD2sXntFymsbY%3D
-
Elliott B, Scolyer RA, Suciu S, Lebecque S, Rimoldi D, Gugerli O, Musat E, Sharma RN, Lienard D, Keilholz U, Testori A, Eggermont A, MacKie R, Robert C, Cook M, Thompson JF, Angevin E, Spatz A (2007) Long-term protective effect of mature DC-LAMP + dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res 13(13):3825-3830
-
(2007)
Clin Cancer Res
, vol.13
, Issue.13
, pp. 3825-3830
-
-
Elliott, B.1
Scolyer, R.A.2
Suciu, S.3
Lebecque, S.4
Rimoldi, D.5
Gugerli, O.6
Musat, E.7
Sharma, R.N.8
Lienard, D.9
Keilholz, U.10
Testori, A.11
Eggermont, A.12
Mackie, R.13
Robert, C.14
Cook, M.15
Thompson, J.F.16
Angevin, E.17
Spatz, A.18
-
38
-
-
34247868145
-
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b
-
17438101 10.1158/1078-0432.CCR-06-1805 1:CAS:528:DC%2BD2sXkt1enu7o%3D
-
Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE (2007) Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13(8):2422-2428
-
(2007)
Clin Cancer Res
, vol.13
, Issue.8
, pp. 2422-2428
-
-
Yurkovetsky, Z.R.1
Kirkwood, J.M.2
Edington, H.D.3
Marrangoni, A.M.4
Velikokhatnaya, L.5
Winans, M.T.6
Gorelik, E.7
Lokshin, A.E.8
-
39
-
-
42049089735
-
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors
-
18381452 10.1158/0008-5472.CAN-07-6822 1:CAS:528:DC%2BD1cXktV2js7o%3D
-
Worschech A, Kmieciak M, Knutson KL, Bear HD, Szalay AA, Wang E, Marincola FM, Manjili MH (2008) Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res 68(7):2436-2446
-
(2008)
Cancer Res
, vol.68
, Issue.7
, pp. 2436-2446
-
-
Worschech, A.1
Kmieciak, M.2
Knutson, K.L.3
Bear, H.D.4
Szalay, A.A.5
Wang, E.6
Marincola, F.M.7
Manjili, M.H.8
-
40
-
-
57149103930
-
Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis
-
19047140 10.1158/0008-5472.CAN-08-1429 1:CAS:528:DC%2BD1cXhsVegtbrK
-
Huang FJ, Steeg PS, Price JE, Chiu WT, Chou PC, Xie K, Sawaya R, Huang S (2008) Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res 68(23):9634-9642
-
(2008)
Cancer Res
, vol.68
, Issue.23
, pp. 9634-9642
-
-
Huang, F.J.1
Steeg, P.S.2
Price, J.E.3
Chiu, W.T.4
Chou, P.C.5
Xie, K.6
Sawaya, R.7
Huang, S.8
-
41
-
-
0036906527
-
Lymphocyte subpopulations and interleukin levels in high-risk melanoma patients treated with high-dose interferon A-2B
-
12478006 10.1097/00000421-200212000-00013
-
Gogas H, Paterakis G, Frangia K, Bafaloukos D, Pectasides D, Kalofonos HP, Loukopoulos D, Stavropoulou-Giokas C, Ioannovich J, Mihm MC Jr (2002) Lymphocyte subpopulations and interleukin levels in high-risk melanoma patients treated with high-dose interferon A-2B. Am J Clin Oncol 25(6):591-596
-
(2002)
Am J Clin Oncol
, vol.25
, Issue.6
, pp. 591-596
-
-
Gogas, H.1
Paterakis, G.2
Frangia, K.3
Bafaloukos, D.4
Pectasides, D.5
Kalofonos, H.P.6
Loukopoulos, D.7
Stavropoulou-Giokas, C.8
Ioannovich, J.9
Mihm, Jr.M.C.10
-
42
-
-
79955561959
-
Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients
-
10.1186/1479-5876-9-52
-
Simons DL, Lee G, Kirkwood JM, Lee PP (2011) Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med 5(9):52-60
-
(2011)
J Transl Med
, vol.5
, Issue.9
, pp. 52-60
-
-
Simons, D.L.1
Lee, G.2
Kirkwood, J.M.3
Lee, P.P.4
-
43
-
-
0038128204
-
High-throughput immunoblotting. Ubiquitin-like protein ISG15 modifies key regulators of signal transduction
-
12582176 10.1074/jbc.M208435200 1:CAS:528:DC%2BD3sXjsVKnsb4%3D
-
Malakhov MP, Kim KI, Malakhova OA, Jacobs BS, Borden EC, Zhang DE (2003) High-throughput immunoblotting. Ubiquitin-like protein ISG15 modifies key regulators of signal transduction. J Biol Chem 278(19):16608-16613
-
(2003)
J Biol Chem
, vol.278
, Issue.19
, pp. 16608-16613
-
-
Malakhov, M.P.1
Kim, K.I.2
Malakhova, O.A.3
Jacobs, B.S.4
Borden, E.C.5
Zhang, D.E.6
-
44
-
-
77951991690
-
Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification
-
20308324 10.1128/MCB.01466-09 1:CAS:528:DC%2BC3cXmtFymsLk%3D
-
Shi HX, Yang K, Liu X, Liu XY, Wei B, Shan YF, Zhu LH, Wang C (2010) Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol Cell Biol 30(10):2424-2436
-
(2010)
Mol Cell Biol
, vol.30
, Issue.10
, pp. 2424-2436
-
-
Shi, H.X.1
Yang, K.2
Liu, X.3
Liu, X.Y.4
Wei, B.5
Shan, Y.F.6
Zhu, L.H.7
Wang, C.8
-
45
-
-
0037443090
-
Protein ISGylation modulates the JAK-STAT signaling pathway
-
12600939 10.1101/gad.1056303 1:CAS:528:DC%2BD3sXhslCqtbk%3D
-
Malakhova OA, Yan M, Malakhov MP, Yuan Y, Ritchie KJ, Kim KI, Peterson LF, Shuai K, Zhang DE (2003) Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev 17(4):455-460
-
(2003)
Genes Dev
, vol.17
, Issue.4
, pp. 455-460
-
-
Malakhova, O.A.1
Yan, M.2
Malakhov, M.P.3
Yuan, Y.4
Ritchie, K.J.5
Kim, K.I.6
Peterson, L.F.7
Shuai, K.8
Zhang, D.E.9
-
46
-
-
77249169773
-
Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection
-
e1121-e1123
-
Chen L, Borozan I, Sun J, Guindi M, Fischer S, Feld J, Anand N, Heathcote J, Edwards AM, McGilvray ID (2010) Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology 138(3):1123-1133, e1121-e1123
-
(2010)
Gastroenterology
, vol.138
, Issue.3
, pp. 1123-1133
-
-
Chen, L.1
Borozan, I.2
Sun, J.3
Guindi, M.4
Fischer, S.5
Feld, J.6
Anand, N.7
Heathcote, J.8
Edwards, A.M.9
McGilvray, I.D.10
|